HomeRENK stock forecast: Record backlog, 2026 outlook

RENK stock forecast: Record backlog, 2026 outlook

RENK Group is a German defence supplier with a record €6.7bn backlog after FY2025 results, as higher European defence spending supports demand and export restrictions remain a near-term risk. Past performance is not a reliable indicator of future results. Explore third-party R3NK price targets.
By Dan Mitchell
Man analyzing financial charts on a computer screen
Photo: Shutterstock

RENK Group AG (R3NK) is trading at €56.18 at 3:34pm UTC 16 March 2026, within a session range of €54.05-€56.21, holding near the top of that intraday band. Past performance is not a reliable indicator of future results.

Support for the stock comes amid continued European rearmament momentum, with Germany's 2026 federal defence budget earmarked at approximately €108bn, a 25% year-on-year increase, as reported by Janus Henderson (Deutsche Welle, 29 January 2026). RENK's own record order backlog of approximately €6.7bn provides multi-year revenue visibility following FY2025 results released on 5 March 2026, which confirmed 19.8% revenue growth to €1.37bn (RENK, 5 March 2026). The company's 2026 guidance targets revenue above €1.5bn, with adjusted EBIT of €255m-€285m, though CEO Alexander Sagel also flagged order delays and export restrictions as near-term headwinds, with roughly €200m in defence orders deferred from Q4 2025 into 2026 (Reuters, 5 March 2026).

RENK stock forecast 2026–2030: Third-party price targets

As of 16 March 2026, third-party RENK stock predictions reflect a broadly constructive stance across coverage, with the stock's post-results pullback from October 2025 highs prompting selective target revisions while the modal rating remains Buy. The following summaries are drawn exclusively from broker notes and consensus data published between 28 February and 16 March 2026.

Warburg Research (Buy reaffirmation, post-results)

Warburg Research analyst Christian Cohrs reaffirms a Buy rating and a €63 12-month R3NK stock forecast, describing the post-results share price weakness as disproportionate to the company's underlying business trajectory. Cohrs cites RENK's record order backlog of €6.68bn and management guidance for revenue above €1.5bn in fiscal 2026 as the primary support for his unchanged constructive view (MarketScreener, 9 March 2026).

Berenberg (Buy maintained, €76 target confirmed)

Berenberg analyst George McWhirter keeps a Buy rating and a €76 12-month price target on R3NK, the highest target among named brokers in the current coverage universe. The confirmation follows RENK's full-year 2025 results, with McWhirter retaining his positive view amid the company's adjusted EBIT guidance of €255m to €285m for fiscal 2026, framing the 2% guidance miss versus prior consensus as manageable rather than structural (MarketScreener, 5 March 2026).

J.P. Morgan (Overweight maintained, €75 target)

J.P. Morgan analyst David Perry maintains an Overweight rating and a €75 12-month price target on R3NK, characterising the Q4 shortfall versus expectations as noise rather than a trend, and describing any further share price weakness as a potential buying opportunity. Perry's note was issued alongside RENK's FY2025 earnings release, with the bank's Overweight thesis resting on the structural multi-year demand cycle underpinning European defence procurement (Trader Times, 6 March 2026).

Deutsche Bank (Buy reaffirmation, €72 target)

Deutsche Bank analyst Christophe Menard reaffirms a Buy rating and an unchanged €72 12-month price target on R3NK, holding this view steady following RENK's record full-year results despite the stock's post-results consolidation. Menard retains his Buy stance, with RENK's 2026 adjusted EBIT guidance midpoint of approximately €270m landing roughly 2% below prior consensus, a gap he treats as within normal estimation variance rather than a thesis-changing development (MarketScreener, 6 March 2026).

MarketScreener (14-analyst consensus, post-results update)

MarketScreener aggregates a 14-analyst consensus for R3NK, with a mean Buy rating, an average 12-month price target of €68.46, and a target range of €53 to €76. The panel spans J.P. Morgan, Goldman Sachs, Deutsche Bank, Berenberg, Jefferies, BNP Paribas, Citigroup, and Kepler Cheuvreux, among others, with MWB Research holding the low-end €53 estimate and Berenberg holding the high at €76 (MarketScreener, 5 March 2026).

Predictions and third-party forecasts are inherently uncertain, as they cannot fully account for unexpected market developments. Past performance is not a reliable indicator of future results.

R3NK stock price: Technical overview

On the daily chart, the R3NK stock price trades at €56.18 as of 3:34pm UTC on 16 March 2026, sitting just below a dense moving-average shelf where the 20-, 50-, 100- and 200-day SMAs cluster near €57, €58, €58 and €64. Price is below all four of those levels, and the 20-over-50 alignment does not apply here because both are above the last price, keeping the near-term trend under pressure.

Momentum is subdued. The 14-day relative strength index reads 46.99, a neutral reading that offers no directional conviction, while the average directional index at 14.67 sits just below the 15 threshold, signalling a weak and poorly defined trend at present.

On the topside, the first reference is the classic R1 pivot at €62.69. A convincing daily close above that level would put the R2 zone near €68.45 back in view. The 200-day EMA at €57.90 and the 20-day SMA at €57.22 form an immediate overhead band that price would need to reclaim before the R1 pivot becomes a realistic test.

On pullbacks, the classic pivot point at €55.90 provides the initial support reference, sitting just below the current last price of €56.18. Losing that level would expose the S1 support at €50.14. The 100-day SMA near €58 acts as resistance overhead rather than a floor from current levels, meaning the pivot and S1 define the near-term downside roadmap (TradingView, 16 March 2026).

This is technical analysis for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any instrument.

RENK share price history (2024–2026)

RENK Group (R3NK) listed on the Frankfurt Stock Exchange in November 2023. The stock was issued at €15 per share, and by the end of 2024 it had climbed sharply on the back of growing European defence spending expectations and a record order backlog.

The data window from July 2025 shows R3NK already trading above €71, reflecting how far the stock had risen in the preceding period. It continued to grind higher through the summer, closing above €87 in late September 2025 before reaching a dataset high of €90.37 on 6 October 2025 as defence procurement momentum built across NATO member states. A sharp reversal followed, with the stock sliding to a dataset low of €47.57 on 2 December 2025 - a drop of approximately 47% from that peak in under two months - as investors digested cautious 2026 guidance and export restriction concerns flagged in the company's results.

R3NK’s stock price recovered through December and into the new year, closing 2025 at €54.08 and opening 2026 at €55.56 on 2 January. R3NK is trading at €56.18 as of 16 March 2026, approximately 3.9% higher year to date from the 30 December 2025 close and roughly 37.8% below the October 2025 dataset high.

Past performance is not a reliable indicator of future results.

RENK (R3NK): Capital.com analyst view

RENK's price trajectory over the past year reflects the broader surge and subsequent recalibration in European defence equities. The stock climbed to a dataset high above €90 in early October 2025, fuelled by accelerating NATO rearmament commitments and a record order backlog, before giving back nearly half that gain by December as investors weighed cautious 2026 guidance and near-term export restrictions. That kind of volatility cuts both ways: the same geopolitical tailwinds that lifted the stock can reverse quickly if diplomatic conditions shift or if defence budget commitments are delayed or scaled back.

Into 2026, RENK carries a constructive fundamental backdrop, with revenue guidance above €1.5bn and an adjusted EBIT range of €255m to €285m, but the stock remains approximately 38% below its October 2025 peak, suggesting that the market is still pricing in execution risk around backlog conversion and free cash flow delivery. Analysts broadly maintain Buy ratings, though target cuts from several brokers after the full-year results highlight that expectations matter as much as headlines, and any further guidance disappointment could weigh on the share price despite the supportive macro environment.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Past performance is not a reliable indicator of future results.

Summary – RENK 2026

Past performance is not a reliable indicator of future results.

FAQ

Who owns the most RENK stock?

Based on RENK Group’s investor relations ownership page, there does not appear to be a single controlling shareholder disclosed in the latest summary. The company shows a large free float of 71.42%, while the largest named holders listed include Rovida Investment Management at 3.63%, Wellington Management at 3.10%, and Norway’s Ministry of Finance at 3.02%. That points to a relatively dispersed shareholder base rather than concentrated ownership.

What is the 5 year RENK share price forecast?

There is no reliable five-year R3NK stock forecast, and long-term share price estimates should be treated with caution. The material covered here focuses on shorter-term third-party analyst targets, which ranged from €63 to €76 as of March 2026, with a 14-analyst average of €68.46. Over a five-year horizon, outcomes could depend on defence spending, backlog conversion, export rules, margins and broader market conditions, all of which can change materially.

Is RENK a good stock to buy?

Whether RENK is a good stock to buy depends on an investor’s objectives, time horizon and tolerance for risk. The article highlights supportive factors, including a record backlog, revenue guidance above €1.5bn for 2026 and continued European defence spending momentum. It also outlines risks, such as export restrictions, deferred orders, execution risk and share price volatility. That balance means the stock may appeal to some investors, but it will not suit everyone.

Could RENK stock go up or down?

RENK stock could move in either direction, depending on how company-specific and external factors develop. On one hand, demand linked to European defence procurement, a sizeable order backlog and broadly positive broker coverage may support the investment case. On the other hand, guidance misses, delays in order conversion, export restrictions or shifts in defence spending expectations could weigh on the share price. Technical indicators in the article also suggest the current trend remains weak rather than decisive.

Should I invest in RENK stock?

This article does not provide investment advice, so it cannot say whether you should invest in RENK stock. A decision like that usually depends on your financial situation, goals, risk tolerance and existing portfolio exposure. The article is designed to outline the main bullish and bearish factors, including broker targets, recent results, backlog visibility and operational risks, so readers can assess the stock in context before making their own decision or seeking independent advice.

Can I trade RENK CFDs on Capital.com?

Yes, you can trade RENK CFDs on Capital.com. Trading share CFDs lets you speculate on price movements without owning the underlying asset and to take long or short positions. However, contracts for difference (CFDs) are traded on margin, and leverage amplifies both profits and losses. You should ensure you understand how CFD trading works, assess your risk tolerance, and recognise that losses can occur quickly.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.